CHRM1 Antibodies are immunoglobulin reagents that bind selectively to epitopes on the M1 muscarinic acetylcholine receptor. These antibodies enable researchers to study receptor localization, expression levels, and functional roles in health and disease .
CHRM1 Antibodies are utilized in diverse experimental contexts:
Western Blot (WB): Detects CHRM1 as bands at ~70 kDa (glycosylated form) or ~55 kDa (A04081) .
Immunohistochemistry (IHC): Localizes CHRM1 in brain regions like the striatum, cortex, and hippocampus, showing enrichment in the striatal matrix but not patches .
Functional Studies: Used to investigate CHRM1’s role in apoptosis resistance via Gq/11 signaling .
Alzheimer’s Disease: CHRM1 protein levels are reduced by >50% in hippocampal tissues of Alzheimer’s patients, correlating with cognitive decline .
Striatal Localization: CHRM1 is abundant in striatal matrix interneurons but absent in patches, suggesting compartment-specific roles in motor control .
CHRM1, alongside M3/M5 receptors, protects cells from DNA damage-induced apoptosis via a poly-basic motif in its C-terminus .
Knockout Validation: Antibodies like AMR-001 show no reactivity in Chrm1⁻/⁻ mice, confirming specificity .
Negative Controls: Cerebellar tissues (low CHRM1 expression) validate antibody specificity in WB/IHC .
Blocking Peptide Preabsorption: Preincubation with antigenic peptides abolishes signal, confirming epitope targeting .